Homrich & Berg Has Increased By $352,618 Its 3M Co (MMM) Holding, Halozyme Therapeutics, Inc. (HALO) Had 5 Bullish Analysts

June 9, 2017 - By Maria Brooks

Among 6 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Halozyme Therapeutics had 9 analyst reports since August 11, 2015 according to SRatingsIntel. Barclays Capital initiated Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Tuesday, September 22. Barclays Capital has “Overweight” rating and $27 target. Piper Jaffray maintained the shares of HALO in report on Friday, September 16 with “Overweight” rating. The company was maintained on Wednesday, March 9 by JMP Securities. On Thursday, November 3 the stock rating was initiated by Deutsche Bank with “Buy”. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Overweight” rating by Barclays Capital on Wednesday, February 24. The firm earned “Market Outperform” rating on Tuesday, August 11 by JMP Securities. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Neutral” rating given on Friday, January 6 by Citigroup. The company was initiated on Wednesday, November 18 by Citigroup. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. See Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings:

06/01/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade

Homrich & Berg increased 3M Co (MMM) stake by 24.25% reported in 2016Q4 SEC filing. Homrich & Berg acquired 1,981 shares as 3M Co (MMM)’s stock rose 7.02%. The Homrich & Berg holds 10,150 shares with $1.81M value, up from 8,169 last quarter. 3M Co now has $123.73 billion valuation. The stock rose 0.14% or $0.29 reaching $206.23 per share. About 86,878 shares traded. 3M Co (NYSE:MMM) has risen 18.59% since June 9, 2016 and is uptrending. It has outperformed by 1.89% the S&P500.

Homrich & Berg decreased Vanguard Star Fd (VXUS) stake by 942,018 shares to 715,109 valued at $32.81M in 2016Q4. It also reduced Schwab Strategic Tr (SCHF) stake by 100,621 shares and now owns 136,608 shares. Vanguard Tax Managed Intl Fd (VEA) was reduced too.

Investors sentiment increased to 0.86 in 2016 Q4. Its up 0.08, from 0.78 in 2016Q3. It is positive, as 67 investors sold MMM shares while 592 reduced holdings. 100 funds opened positions while 464 raised stakes. 383.70 million shares or 2.52% more from 374.26 million shares in 2016Q3 were reported. Meridian Investment Counsel Incorporated reported 1.25% in 3M Co (NYSE:MMM). Caisse De Depot Et Placement Du Quebec holds 1.11% or 2.46 million shares in its portfolio. Moreover, Fincl Advisory Service has 0.11% invested in 3M Co (NYSE:MMM) for 1,995 shares. Calvert Mgmt Inc reported 44,607 shares or 0.3% of all its holdings. Northeast Invest Mngmt accumulated 145,995 shares or 2.5% of the stock. Private Wealth Prns Ltd Com holds 0.66% of its portfolio in 3M Co (NYSE:MMM) for 15,470 shares. Signaturefd Ltd Limited Liability Company accumulated 3,730 shares. Old Second State Bank Of Aurora reported 0.2% in 3M Co (NYSE:MMM). Chevy Chase Trust Incorporated holds 694,344 shares. Cornerstone Cap Inc holds 2,315 shares or 0.09% of its portfolio. Schnieders Management Limited Com has 1.19% invested in 3M Co (NYSE:MMM). Martin Currie Limited invested in 0.05% or 2,700 shares. Private Wealth Advisors Incorporated has 6,614 shares. Fieldpoint Private has 0.54% invested in 3M Co (NYSE:MMM) for 4,610 shares. Cambridge Company has invested 1.48% in 3M Co (NYSE:MMM).

Since December 13, 2016, it had 0 insider buys, and 15 selling transactions for $31.62 million activity. $1.53M worth of 3M Co (NYSE:MMM) was sold by Keel Paul A. 14,766 shares were sold by McGrath Marlene Mary, worth $2.88 million. Shares for $1.90 million were sold by Vale Michael G.. The insider Gangestad Nicholas C sold 2,888 shares worth $523,613. $5.00 million worth of 3M Co (NYSE:MMM) shares were sold by THULIN INGE G. Shares for $2.11 million were sold by Delgado Joaquin. Shin Hak Cheol had sold 47,528 shares worth $8.41M on Wednesday, February 8.

Among 11 analysts covering 3M (NYSE:MMM), 5 have Buy rating, 2 Sell and 4 Hold. Therefore 45% are positive. 3M had 42 analyst reports since July 24, 2015 according to SRatingsIntel. Credit Suisse upgraded the stock to “Outperform” rating in Friday, September 25 report. The firm has “Outperform” rating by Credit Suisse given on Tuesday, March 15. The stock has “Buy” rating by Barclays Capital on Friday, April 28. Jefferies maintained the stock with “Buy” rating in Friday, May 26 report. On Wednesday, March 30 the stock rating was maintained by UBS with “Buy”. The firm has “Underperform” rating by RBC Capital Markets given on Wednesday, December 16. The rating was maintained by Citigroup with “Buy” on Tuesday, April 19. The firm earned “Sell” rating on Monday, November 21 by Goldman Sachs. As per Wednesday, March 30, the company rating was maintained by Bernstein. RBC Capital Markets maintained the stock with “Underperform” rating in Wednesday, October 26 report.

Investors sentiment increased to 1.23 in Q4 2016. Its up 0.27, from 0.96 in 2016Q3. It increased, as 20 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 26 funds opened positions while 53 raised stakes. 108.31 million shares or 4.02% more from 104.12 million shares in 2016Q3 were reported. Sg Americas Secs Limited Co owns 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 70,344 shares. Trexquant Investment Limited Partnership, a Connecticut-based fund reported 35,009 shares. Senzar Asset Management Ltd Co stated it has 1.23M shares or 3.21% of all its holdings. Moreover, Invesco Limited has 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 2.34 million shares. Aqr Cap Management Ltd Liability Company accumulated 15,546 shares. Macquarie Group Limited holds 460,000 shares. Stephens Ar stated it has 11,000 shares or 0% of all its holdings. Burt Wealth Advisors has invested 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). 50,000 were reported by Moore Capital Mgmt L P. Blackrock Japan accumulated 2,662 shares. New York State Common Retirement Fund invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Rhenman & Partners Asset Ab has invested 0.34% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Bancorporation Of Montreal Can owns 3,415 shares. Allianz Asset Mngmt Ag reported 134,982 shares.

About 23,114 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since June 9, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.